New Clinical Trial Evidence of SurroSense Rx® to be Presented at EASD 2018

SurroSense Rx shows effectiveness of protecting people with diabetes from foot ulcers

Berlin, Germany, September 4, 2018  – Results from a randomized clinical trial ran by Manchester Metropolitan University showed the SurroSense Rx provided a 71 per cent reduction in foot ulcers over an 18-month long study. Manchester Metropolitan University will be presenting their findings at EASD 2018 (European Association for the Study of Diabetes) at the Messe Berlin Exhibition Halls in Berlin-Charlottenburg, Germany on October 2, 2018.

The results of the trial will be presented during Session 02 – OP 02 Foot Prints titled “Novel plantar pressure-sensing smart insoles reduce foot ulcer incidence in “high risk” diabetic patients: a longitudinal study.” Please click here for session details and how to register.

“This critical research adds to a growing body of evidence demonstrating effectiveness of the SurroSense Rx smart insole system in reducing unnecessary foot complications in people with diabetes. We value the contribution by Manchester Metropolitan University in furthering research that focuses on prevention of foot complications and amputation, and improvement of mobility and quality of life, in people living with diabetes.” said Dr. Breanne Everett, co-founder and CEO of Orpyx Medical Technologies Inc.

The European Association for the Study of Diabetes e.V. (EASD) is a non-profit, medical scientific association. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

EASD holds its Annual Meeting in a different European city each year with more than 15,000 delegates from over 130 countries attending. The scientific programme includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field.

About Orpyx® Medical Technologies Inc.
Founded in 2010, Orpyx Medical Technologies empowers people with diabetes to maintain foot health and mobility. Orpyx’s core product, SurroSense Rx®, helps prevent foot ulcers and limb loss through FDA-cleared, advanced foot sensor technology and analytics, delivered in an easy-to-use ultra thin insole. Orpyx’s other products are used by researchers to access clinical-grade plantar pressure measurement data for health and human performance applications. Orpyx is focused on collaborating with stakeholders around the world to achieve a healthcare future that is prevention-focused and sustainable in cost. Learn more at www.orpyx.com.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501